Nevro’s Pain Treatment AI System Approved

Nevro has received FDA approval for its Senza HFX iQ artificial intelligence-based spinal cord stimulation system that personalizes the treatment of chronic back and leg pain, including non-surgical back pain and diabetic neuropathy.

The system, which includes an implantable pulse generator and the company’s proprietary software, is designed to help patients optimize and maintain long-term pain relief and improved quality of life.

The algorithm was developed to take direct input from each patient on pain and quality of life measures and then recommend treatment changes.

The company will begin a limited release in the U.S. this quarter, with a broad U.S. launch planned for early 2023.